2009
DOI: 10.1056/nejmoa0906453
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Vaccination with recent seasonal nonadjuvanted or adjuvanted influenza vaccines induced little or no cross-reactive antibody response to 2009 H1N1 in any age group. Persons under the age of 30 years had little evidence of cross-reactive antibodies to the pandemic virus. However, a proportion of older adults had preexisting cross-reactive antibodies.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

103
1,012
20
28

Year Published

2010
2010
2013
2013

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 1,142 publications
(1,163 citation statements)
references
References 23 publications
103
1,012
20
28
Order By: Relevance
“…Baseline seroprevalence was highest in age‐group 80 years and older as published previously 13, 14. The lowest baseline seroprevalence was in the youngest age‐group (0–9 years), while in age‐groups 20–49 and 50–79, the baseline seroprevalence was intermediate.…”
Section: Resultssupporting
confidence: 79%
“…Baseline seroprevalence was highest in age‐group 80 years and older as published previously 13, 14. The lowest baseline seroprevalence was in the youngest age‐group (0–9 years), while in age‐groups 20–49 and 50–79, the baseline seroprevalence was intermediate.…”
Section: Resultssupporting
confidence: 79%
“…For example, older individuals in some Asian countries had lower levels of cross‐reactive antibodies prior to widespread circulation of the pandemic strain than did individuals in other regions. However, this was not a universal finding for all Asian countries and may be a reflection of the age groups we chose in this meta‐analysis because we collapsed elderly age categories into a single unit (≥65 years of age): some studies observed differences among the elderly (>65 years old) versus very senior individuals (i.e., >80 years old, e.g.,25, 41, 52, 60). We note that regional differences did not persist when only looking at cumulative incidence from studies in which two sets of sera from one population were tested in the same laboratory using the same methodology or in post‐pandemic seroprevalence.…”
Section: Discussionmentioning
confidence: 99%
“…Evidence from the past pandemics suggests that exposure to influenza virus in childhood could provide life‐long immunity. In particular, recent studies have shown that seniors enjoyed partial clinical protection during the 2009 pandemic through pre‐existing cross‐reactive antibodies to the 2009 A/H1N1pdm virus 94 . Here, we controlled for prior influenza exposure by including terms for age and baseline serostatus in the regression models.…”
Section: Discussionmentioning
confidence: 99%